Sarepta Therapeutics’ (SRPT) Sell Rating Reiterated at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reaffirmed by investment analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They presently have a $75.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential downside of 37.63% from the stock’s current price.

Several other analysts also recently issued reports on the company. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. UBS Group upped their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. StockNews.com cut shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Piper Sandler lowered their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $178.71.

Sarepta Therapeutics Stock Down 4.4 %

SRPT stock opened at $120.25 on Thursday. The firm has a market cap of $11.49 billion, a PE ratio of 96.20 and a beta of 0.77. Sarepta Therapeutics has a 1 year low of $89.92 and a 1 year high of $173.25. The company has a fifty day simple moving average of $123.46 and a 200 day simple moving average of $131.44. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the sale, the director now owns 22,840 shares of the company’s stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Hedge funds have recently modified their holdings of the company. Envestnet Portfolio Solutions Inc. acquired a new stake in Sarepta Therapeutics during the 2nd quarter valued at $201,000. Fifth Third Bancorp increased its stake in shares of Sarepta Therapeutics by 22.0% in the second quarter. Fifth Third Bancorp now owns 1,220 shares of the biotechnology company’s stock valued at $193,000 after buying an additional 220 shares in the last quarter. New York State Teachers Retirement System acquired a new stake in shares of Sarepta Therapeutics in the second quarter valued at $12,051,000. Retirement Systems of Alabama bought a new position in shares of Sarepta Therapeutics in the second quarter valued at about $18,433,000. Finally, Banque Pictet & Cie SA acquired a new position in Sarepta Therapeutics during the 2nd quarter worth about $5,455,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.